142 related articles for article (PubMed ID: 30551478)
41. PHF6 Degrees of Separation: The Multifaceted Roles of a Chromatin Adaptor Protein.
Todd MA; Ivanochko D; Picketts DJ
Genes (Basel); 2015 Jun; 6(2):325-52. PubMed ID: 26103525
[TBL] [Abstract][Full Text] [Related]
42. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
[TBL] [Abstract][Full Text] [Related]
43. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
[TBL] [Abstract][Full Text] [Related]
44. Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK.
Liu Y; Ge J; Li Q; Gu L; Guo X; Ma ZG; Zhu YP
Neoplasma; 2013; 60(1):101-10. PubMed ID: 23067223
[TBL] [Abstract][Full Text] [Related]
45. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
Junk S; Cario G; Wittner N; Stanulla M; Scherer R; Schlegelberger B; Schrappe M; von Neuhoff N; Lauten M
Klin Padiatr; 2015 May; 227(3):123-30. PubMed ID: 25985447
[TBL] [Abstract][Full Text] [Related]
46. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.
Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB
BMC Genomics; 2014 Jun; 15(1):416. PubMed ID: 24885906
[TBL] [Abstract][Full Text] [Related]
47. The Effect of Prednisolone on miR 15a and miR16-1 Expression Levels and Apoptosis in Acute Lymphoblastic Leukemia Cell Line: CCRF-CEM.
Azimi A; Hagh MF; Yousefi B; Rahnama MA; Khorrami A; Heydarabad MZ; Najafpour M; Hallajzadeh J; Ghahremani A
Drug Res (Stuttg); 2016 Aug; 66(8):432-5. PubMed ID: 27281445
[TBL] [Abstract][Full Text] [Related]
48. 1H, 13C and 15N resonance assignments and secondary structure of the human PHF6-ePHD1 domain.
Bao Y; Liu Z; Zhang J; Wu J; Shi Y
Biomol NMR Assign; 2016 Apr; 10(1):1-4. PubMed ID: 26286319
[TBL] [Abstract][Full Text] [Related]
49. Further clinical delineation of the Börjeson-Forssman-Lehmann syndrome in patients with PHF6 mutations.
Carter MT; Picketts DJ; Hunter AG; Graham GE
Am J Med Genet A; 2009 Feb; 149A(2):246-50. PubMed ID: 19161141
[TBL] [Abstract][Full Text] [Related]
50. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
[TBL] [Abstract][Full Text] [Related]
51. PHF6 mutations in adult acute myeloid leukemia.
Van Vlierberghe P; Patel J; Abdel-Wahab O; Lobry C; Hedvat CV; Balbin M; Nicolas C; Payer AR; Fernandez HF; Tallman MS; Paietta E; Melnick A; Vandenberghe P; Speleman F; Aifantis I; Cools J; Levine R; Ferrando A
Leukemia; 2011 Jan; 25(1):130-4. PubMed ID: 21030981
[TBL] [Abstract][Full Text] [Related]
52. Protein and gene expression analysis of Phf6, the gene mutated in the Börjeson-Forssman-Lehmann Syndrome of intellectual disability and obesity.
Voss AK; Gamble R; Collin C; Shoubridge C; Corbett M; Gécz J; Thomas T
Gene Expr Patterns; 2007 Oct; 7(8):858-71. PubMed ID: 17698420
[TBL] [Abstract][Full Text] [Related]
53. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
54. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative.
Ganguly A; Banerjee K; Chakraborty P; Das S; Sarkar A; Hazra A; Banerjee M; Maity A; Chatterjee M; Mondal NB; Choudhuri SK
Biomed Pharmacother; 2011 Sep; 65(6):387-94. PubMed ID: 21715129
[TBL] [Abstract][Full Text] [Related]
55. Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemia cell lines.
Ooko E; Alsalim T; Saeed B; Saeed MEM; Kadioglu O; Abbo HS; Titinchi SJJ; Efferth T
Toxicol Appl Pharmacol; 2016 Aug; 305():216-233. PubMed ID: 27318188
[TBL] [Abstract][Full Text] [Related]
56. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
[TBL] [Abstract][Full Text] [Related]
57. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
58. Investigation of
Khanzadeh T; Hagh MF; Talebi M; Yousefi B; Azimi A; Hossein Pour Feizi AA; Baradaran B
Blood Res; 2018 Mar; 53(1):53-60. PubMed ID: 29662863
[TBL] [Abstract][Full Text] [Related]
59. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
60. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
